Blog

Dr. Jagannath on Potential of Immunotherapy in Multiple Myeloma – OncLive


OncLive

Dr. Jagannath on Potential of Immunotherapy in Multiple Myeloma
OncLive
Immunotherapy approaches may overcome mutational burdens or drug resistance in the cancer cells of this disease, says Jagannath. Monoclonal antibodies such as daratumumab (Daralex) and elotuzumab (Empliciti) are being used in newly diagnosed …

2017-03-27 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.